Value proposition

Superior and effective microbiome therapeutics

CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome.

CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham.

CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific therapeutics to the gut. CHAIN’s Clostridium Assisted Drug Delivery (CADDTM) delivery platform is highly differentiated and supports a therapeutic product pipeline for a wide range of clinical indications including localised infection, inflammation and CNS signalling.

Our lead asset is an engineered strain that secretes a novel and potent anti-inflammatory molecule targeting Inflammatory Bowel Disease, a chronic gut disease affecting millions worldwide.

Metabolic engineering, Microbiology, Synthetic biology, Chiral chemical synthesis, Anaerobe, Clostridia, and microbiome